Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products

July 31, 2024 Media Relations, Medical Communications, Pharmacovigilance, US Healthcare & Trade Press FDA, Gastrointestinal tract, compunded injectable, dosage, hospitalisation, pharmaceutical, warning

This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing errors associated with compounded injectable …
News

AstraZeneca’s AMPLIFY trial interim analysis demonstrates positive results for Calquence plus venetoclax

July 30, 2024 Research and Development AstraZeneca, Haematology, chronic lymphocytic leukaemia, haematology, trial analysis

AstraZeneca has announced positive high-level results from an interim analysis for its AMPLIFY phase 3 trial, combining AstraZeneca’s Calquence (acalabrutinib) …
News

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI  in combination with MEKTOVI  for the treatment of adult patients with advanced non-small cell lung cancer  NSCLC) with a BRAFV600E mutation

July 29, 2024 Clinical Trial Services BRAF mutation, CHMP, EMA, Oncology, Pierre Fabre Laboratories, colorectal cancer, european studies, non-small cell lung cancer

Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee for Medicinal Products Human use …
News

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

July 29, 2024 Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma

Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …
News

Calliditas Therapeutics announces positive phase 2b data in Primary Biliary Cholangitis trial

July 26, 2024 Research and Development Calliditas, Hepatology, clinical trials, elevated liver stiffness, primary biliary cholangitis

 Calliditas Therapeutics AB today announced that the phase 2b TRANSFORM trial met its primary endpoint. The trial showed statistically significant …
News
alzheimers_brain

AC Immune’s pTau-targeting immunotherapy awarded Fast Track designation by FDA

July 26, 2024 Research and Development AC Immune, Alzheimer's disease, Neurology, clinical trials, fast track designation, immunotherapy, tau protein

Clinical-stage biopharmaceutical company AC Immune announced that the US Food and Drug Administration (FDA) has granted its Alzheimer’s disease (AD) …
News

ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy

July 23, 2024 Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy

GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …
News

Results from Sanofi’s ALTUVIIIO XTEND-Kids phase 3 trial published in NEJM

July 22, 2024 Research and Development Altuviiio, Haematology, Sanofi, haemophilia

Sanofi has announced that full results from the XTEND-Kids phase 3 study were published in The New England Journal of …
News

Brainomix and Boehringer Ingelheim enter strategic partnership

July 19, 2024 Research and Development Boehringer Ingelheim, Brainomix, Pharmacy, fibrosing lung disease, partnership

Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for a collaborative programme surrounding the …
News

Camurus shares phase 3 results from ACROINNOVA 2 study

July 16, 2024 Research and Development Camurus, Pharmacy, acromegaly, clinical trial, injection

Camurus has announced positive results from its 52-week phase 3 open-label ACROINNOVA 2 study, which assessed the safety and efficacy …
News

AI-powered prognosis test company Spotlight Medical secures €6.2m in seed funding

July 15, 2024 Research and Development Oncology, Precision Medicine, Spotlight Medical, artificial intelligence, oncology, seed funding

Start-up Spotlight Medical has announced it has raised €6.2m in a seed funding round led by Kurma Partners and Heal Capital. …
News
heart-2372134_640

ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models

July 15, 2024 Research and Development Cardiology, RNAi therapeutics, Sirnaomics, biopharmaceutical, cardiovascular, investigational new drug

Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced the completion of IND-enabling studies …
News
body scan

Pfizer selects once-daily obesity drug for advancement

July 12, 2024 Research and Development Obesity, Pfizer Inc, clinical trials, obesity

Pfizer has announced the selection of its preferred once-daily modified release formulation for danuglipron, with a plan to conduct dose …
News
lung_cancer_on_chest_x-ray

Imidex and Spesana collaborate over impact of AI in lung nodule and mass detection

July 12, 2024 Research and Development Imidex, Oncology, Spesana, artificial intelligence, cancer detection, lung cancer

Personalised medicine technology company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to research AI’s …
News

iOnctura expands clinical trial programme for NSCLC

July 9, 2024 Research and Development NSCLC, Oncology, clinical trial, iOnctura, lung cancer

iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026